Basf Se Corporation

Metanomics Gmbh

Volker Strauss

Ralf Looser

Tilmann B Walk

Michael Manfred Herold

Edgar Leibold

Jan C Wiemer

Bennard Van Ravenzwaay

Georgia Coelho Palermo Cunha

Werner Mellert

Alexandre Prokoudine

Eric Fabian

Hennicke Kamp

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection including characteristic values of at least five metabolites, a data storage medium including data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

Means and methods for assessing increased peroxisomal proliferation

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing the pro-pathological effect of compounds which are inducing liver enzymes. It also relates to a method of determining whether a compound is capable of exhibiting pro-pathological effects on the liver by enzyme induction in a subject and to a method of identifying a drug for treating the pro-pathological effect of liver enzyme induction. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five analytes, a data storage medium comprising said data collection, and a system and a device for diagnosing the pro-pathological effect of liver enzyme induction. Finally, the present invention pertains to the use of a group of analytes or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing the pro-pathological effect of liver enzyme induction in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed. The liver enzyme induction markers are mainly selected from free fatty acids, but also include various phosphatidylcholines, galactose, 3- and 5-Methoxysphingosine, Cholesterol, Threonic acid, 1,2-Dioleoyl-sn-glycero-3-phosphatidyl-L-serine, Glycerol, Glycerophosphate, Dodecanol, myo-Inositol-2-monophosphate.

Methods related to liver enzyme induction as a predisposition for liver toxicity and diseases or disorders associated therewith

The present invention pertains to the field of toxicological assessments of risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection of characteristic values of at least five metabolites, a data storage medium for the data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver toxicity. It also relates to a method of determining whether a compound is capable of inducing such liver toxicity in a subject and to a method of identifying a drug for treating liver toxicity. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing liver toxicity. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing liver toxicity in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed. The liver toxicity markers are mainly selected from free fatty acids, but also include various phosphatidylcholines, Hydroxyphenylpyruvic acid, alpha-Tocopherol, Cholesterol, myo-Inositol-2-monophosphate, 4-Hydroxysphinganine, Ceramide (d18:1, C24:1), Ceramide (d18:2, C24:0), Sphingomyelin (d18:1, C16:0), 1,2-Dioleoyl-sn-glycero-3-phosphatidyl-L-serine, 18:1 Lyso Phosphatidylcholine, Coenzyme Q9, Glucose, Glycerol, Glycerophosphates, Phosphate, 5-Methoxysphingosine, erythrosphingosine, Threonine, Diacylglycerides and Triacylglycerides.

Method for diagnosing liver toxicity with sex specific biomarkers

The present invention relates to a method for diagnosing hemolytic anemia or a predisposition thereof. It also relates to a method of determining whether a compound is capable of inducing hemolytic anemia in a subject and to a method of identifying a drug for treating hemolytic anemia. Furthermore, the present invention relates to a data collection comprising characteristic values of metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing hemolytic anemia. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing hemolytic anemia in a subject.

Growing community of inventors

Bad Dürkheim, Germany

Volker Strauss